Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Moreau, Philippe; Chari, Ajai; Martínez-López, Joaquín; Haenel, Mathias; Touzeau, Cyrille; Ailawadhi, Sikander; Besemer, Britta; Rubia, Javier de la; Encinas, Cristina; Mateos, Maria Victoria; Salwender, Hans; Rodríguez-Otero, Paula; Hulin, Cyrille; Karlin, Lionel; Sureda, Anna; Bargay, Joan; Benboubker, Lotfi; Rosiñol, Laura; Tarantolo, Stefano; Terebelo, Howard; Yang, Shiyi; Wang, Jianping; Nnane, Ivo; Qi, Ming; Kosh, Michele; Delioukina, María; Goldschmidt, Hartmut

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Daratumumab is approved in many countries as monotherapy and in combination regimens for relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma [1,2,3]. Daratumumab-based combinations have also demonstrated encouraging efficacy in lenalidomide-refractory RRMM [4, 5]. Carfil...

Descripción completa

Detalles Bibliográficos
Autores:	Moreau, Philippe, Chari, Ajai, Martínez-López, Joaquín, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, Rubia, Javier de la, Encinas, Cristina, Mateos, Maria Victoria, Salwender, Hans, Rodríguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, María, Goldschmidt, Hartmut
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2023
País:	España
Institución:	Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:	DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:	oai:digital.csic.es:10261/347169
Acceso en línea:	http://hdl.handle.net/10261/347169
Access Level:	acceso abierto
Palabra clave:	Cancer therapy Drug therapy

id	ES_695c19f07db8327153a4f5a947f6390e
oai_identifier_str	oai:digital.csic.es:10261/347169
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUSMoreau, PhilippeChari, AjaiMartínez-López, JoaquínHaenel, MathiasTouzeau, CyrilleAilawadhi, SikanderBesemer, BrittaRubia, Javier de laEncinas, CristinaMateos, Maria VictoriaSalwender, HansRodríguez-Otero, PaulaHulin, CyrilleKarlin, LionelSureda, AnnaBargay, JoanBenboubker, LotfiRosiñol, LauraTarantolo, StefanoTerebelo, HowardYang, ShiyiWang, JianpingNnane, IvoQi, MingKosh, MicheleDelioukina, MaríaGoldschmidt, HartmutCancer therapyDrug therapyDaratumumab is approved in many countries as monotherapy and in combination regimens for relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma [1,2,3]. Daratumumab-based combinations have also demonstrated encouraging efficacy in lenalidomide-refractory RRMM [4, 5]. Carfilzomib is approved as monotherapy and in combination regimens, including daratumumab and dexamethasone (D-Kd), for RRMM [6]. In the phase 3 CANDOR study, D-Kd (intravenous [IV] daratumumab; carfilzomib 56 mg/m2 twice weekly) improved progression-free survival (PFS) versus Kd in the overall population and lenalidomide-refractory patients [7, 8]. In the phase 3 A.R.R.O.W. study, once-weekly carfilzomib (70 mg/m2) significantly prolonged PFS versus twice-weekly carfilzomib (27 mg/m2), providing a safe and more convenient Kd dosing regimen [9].These studies (ClinicalTrials.gov Identifiers: NCT03412565 and NCT01998971) were sponsored by Janssen Research & Development, LLC.Springer NatureJanssen Research and DevelopmentConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2024202420232024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_545bPublisher's versioninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/contributionToPeriodicalhttp://hdl.handle.net/10261/347169reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at 10.1038/s41408-023-00805-xhttp://dx.doi.org/10.1038/s41408-023-00805-xSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3471692026-05-22T06:33:51Z
dc.title.none.fl_str_mv	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
spellingShingle	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS Moreau, Philippe Cancer therapy Drug therapy
title_short	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_full	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_fullStr	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_full_unstemmed	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_sort	Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
dc.creator.none.fl_str_mv	Moreau, Philippe Chari, Ajai Martínez-López, Joaquín Haenel, Mathias Touzeau, Cyrille Ailawadhi, Sikander Besemer, Britta Rubia, Javier de la Encinas, Cristina Mateos, Maria Victoria Salwender, Hans Rodríguez-Otero, Paula Hulin, Cyrille Karlin, Lionel Sureda, Anna Bargay, Joan Benboubker, Lotfi Rosiñol, Laura Tarantolo, Stefano Terebelo, Howard Yang, Shiyi Wang, Jianping Nnane, Ivo Qi, Ming Kosh, Michele Delioukina, María Goldschmidt, Hartmut
author	Moreau, Philippe
author_facet	Moreau, Philippe Chari, Ajai Martínez-López, Joaquín Haenel, Mathias Touzeau, Cyrille Ailawadhi, Sikander Besemer, Britta Rubia, Javier de la Encinas, Cristina Mateos, Maria Victoria Salwender, Hans Rodríguez-Otero, Paula Hulin, Cyrille Karlin, Lionel Sureda, Anna Bargay, Joan Benboubker, Lotfi Rosiñol, Laura Tarantolo, Stefano Terebelo, Howard Yang, Shiyi Wang, Jianping Nnane, Ivo Qi, Ming Kosh, Michele Delioukina, María Goldschmidt, Hartmut
author_role	author
author2	Chari, Ajai Martínez-López, Joaquín Haenel, Mathias Touzeau, Cyrille Ailawadhi, Sikander Besemer, Britta Rubia, Javier de la Encinas, Cristina Mateos, Maria Victoria Salwender, Hans Rodríguez-Otero, Paula Hulin, Cyrille Karlin, Lionel Sureda, Anna Bargay, Joan Benboubker, Lotfi Rosiñol, Laura Tarantolo, Stefano Terebelo, Howard Yang, Shiyi Wang, Jianping Nnane, Ivo Qi, Ming Kosh, Michele Delioukina, María Goldschmidt, Hartmut
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Janssen Research and Development Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv	Cancer therapy Drug therapy
topic	Cancer therapy Drug therapy
description	Daratumumab is approved in many countries as monotherapy and in combination regimens for relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma [1,2,3]. Daratumumab-based combinations have also demonstrated encouraging efficacy in lenalidomide-refractory RRMM [4, 5]. Carfilzomib is approved as monotherapy and in combination regimens, including daratumumab and dexamethasone (D-Kd), for RRMM [6]. In the phase 3 CANDOR study, D-Kd (intravenous [IV] daratumumab; carfilzomib 56 mg/m2 twice weekly) improved progression-free survival (PFS) versus Kd in the overall population and lenalidomide-refractory patients [7, 8]. In the phase 3 A.R.R.O.W. study, once-weekly carfilzomib (70 mg/m2) significantly prolonged PFS versus twice-weekly carfilzomib (27 mg/m2), providing a safe and more convenient Kd dosing regimen [9].
publishDate	2023
dc.date.none.fl_str_mv	2023 2024 2024 2024
dc.type.none.fl_str_mv	info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_545b Publisher's version info:eu-repo/semantics/publishedVersion
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/contributionToPeriodical
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/10261/347169
url	http://hdl.handle.net/10261/347169
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	The underlying dataset has been published as supplementary material of the article in the publisher platform at 10.1038/s41408-023-00805-x http://dx.doi.org/10.1038/s41408-023-00805-x Sí
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Springer Nature
publisher.none.fl_str_mv	Springer Nature
dc.source.none.fl_str_mv	reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str	Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str	DIGITAL.CSIC. Repositorio Institucional del CSIC
collection	DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869410024554496000
score	15,812429

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Similares en LA Referencia